Morgan Stanley Maintains Overweight on Zealand Pharma, Raises Price Target to $32

Morgan Stanley maintains Zealand Pharma (NASDAQ:ZEAL) with a Overweight and raises the price target from $30 to $32.

Benzinga · 11/15/2019 13:39

Morgan Stanley maintains Zealand Pharma (NASDAQ:ZEAL) with a Overweight and raises the price target from $30 to $32.